Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Prefe... ( WALTHAM Mass. Sept. 15 /- Inverne...)

Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock

Date:9/15/2008

WALTHAM, Mass., Sept. 15 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (Amex: IMA), a leading provider of near-patient diagnostics, monitoring and health management solutions, today declared a dividend of $4.77 per share on its Series B Convertible Perpetual Preferred Stock (Amex: IMA.PR.B). The dividend will be paid in shares of Series B stock in an amount per share equal to the quotient of (a) $4.77 divided by (b) 97% of the average of the volume-weighted average price per share of the Series B stock on the American Stock Exchange for each of the five consecutive trading days ending on the second trading day immediately prior to the record date of the dividend. Inverness will pay cash in lieu of any fractional shares resulting from the dividend. The dividend is payable on October 15, 2008 to holders of record of Series B stock at the close of business on October 1, 2008.

This is the first dividend that the Company has declared and will pay on its Series B stock, and such payment will cover the amount of all dividends accrued from May 9, 2008, the original issuance date of the Series B stock, through September 30, 2008.

For more information about Inverness Medical Innovations, please visit our website at http://www.invernessmedical.com.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inv
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:12/16/2009)... Trial conducted pursuant to Special Protocol Assessment ... QUEBEC CITY, Dec. 16 /PRNewswire-FirstCall/ - AEterna ... AEZ) (the "Company"), a global biopharmaceutical company ... announced the initiation, by its partner Keryx ... Phase 3 registration clinical trial for perifosine ...

(Date:12/16/2009)... Nu-Tek BioSciences, LLC introduces HSP-A Soy Peptone. HSP A has ... , ... (PRWEB) December 16, 2009 -- Nu-Tek BioSciences, ... by introducing HSP-A Soy Peptone. HSP-A, previously manufactured by Nutricepts, ... is proven to improve growth rates and yields. HSP-A has ...

(Date:12/15/2009)... BioEnergy Institute (JBEI), one of three Department of Energy ... time-stamping service to protect its valuable intellectual property. ... ... (PRWEB) December 15, 2009 -- Surety, LLC , ... , today announced that the Joint BioEnergy Institute (JBEI), ...

(Date:12/15/2009)... NEW YORK, Dec. 15 Reportlinker.com ... is available in its catalogue: ,, ... - Market Forecasts to 2015, Pipeline Analysis ... http://www.reportlinker.com/p0168104/The-Future-of-Orphan-Diseases-Therapeutics---Market-Forecasts-to-2015-Pipeline-Analysis-and-Reimbursement.html ,, Summary ... latest research "The Future of Orphan Diseases ...

[0] AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma [0] Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone [0] Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property [0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement

... for antibody therapeutics, BASEL, Switzerland, Sept. 24 ... has completed the acquisition of 100% of the ... (TSX: ARI). On,September 19th, the Ontario Superior Court, ... the security holders and announced in a,press release ...

... Pharmacogenomics Offers a Prescription for Progress, WATERBURY, ... is joining with Genomas(R), a biomedical company advancing,DNA-guided ... DNA-Guided Medicine and the Path to Personalized Health ... meeting. Hartford Hospital is providing,continuing medical education credits ...

... 100 Private Companies" Event in October , ... Conway, ... of 3D imaging for facial biometric systems, today announced that it ... by Business NH Magazine. Recognized for its impressive growth, Animetrics was ...

Other Biology Technology:Roche completes acquisition of ARIUS 2 Connecticut State Medical Society and Genomas Co-Sponsor Forum on DNA-Guided Medicine and the Path to Personalized Health Care 2 Animetrics Inc. Named One of Business NH Magazine's '10 Companies to Watch' for its Significant Revenue Growth 2

Roche completes acquisition of ARIUS Connecticut State Medical Society and Genomas Co-Sponsor Forum on DNA-Guided Medicine and the Path to Personalized Health Care Animetrics Inc. Named One of Business NH Magazine's '10 Companies to Watch' for its Significant Revenue Growth

(Date:12/16/2009)... our planet for more than 4 billion years before ... as many eons more. That suggests they may have ... Aviv University bacteria expert Prof. Eshel Ben-Jacob of the ... grounded in the study of bacteria, presents compelling evidence ... people should not automatically opt for the swine flu ...

(Date:12/16/2009)... Dec. 1 GestureTek Inc. today ... 3.0 - a turnkey, portable, plug and ... exhibits, entertainment and touring promotions. GestureTek is ... patents in camera-enabled gesture recognition technology for ... Guaranteed for quality, the CUBE has TUV, ...

(Date:12/16/2009)... IgeaCare Solutions Inc. is pleased to ... healthcare communications company previously operating as IgeaCare Systems ... move forward under new leadership and funding. ,, ... to the position of Chief Executive Officer. Under ... providing a superior servicing and support model; fast ...

Breaking Biology News(10 mins):Bacteria wouldn't opt for a swine flu shot 2 Bacteria wouldn't opt for a swine flu shot 3 GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2 GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 3 IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2 A WIT Technologies Releases World 26apos 3Bs First Low Cost C Stamp 28TM 29 Based Biotechnology Laboratory in a Box 12572 1 A WIT Technologies Releases World 26apos 3Bs First Low Cost C Stamp 28TM 29 Based Biotechnology Laboratory in a Box 12572 2 Doctors Can Chat Online While Job Searching 48553 1 Doctors Can Chat Online While Job Searching 48553 2 Doctors Can Chat Online While Job Searching 48553 3 American Otological Society 2009 Recipient For the 26quot 3BAward of Merit 26quot 3B Goes to Dr William H Lippy of Warren Ohio 48549 1 American Otological Society 2009 Recipient For the 26quot 3BAward of Merit 26quot 3B Goes to Dr William H Lippy of Warren Ohio 48549 2

[0] Bacteria wouldn't opt for a swine flu shot [0] GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits [0] IgeaCare Solutions Inc. Emerges Under New Leadership and Funding

... University of New Hampshire (UNH) have found that invasive ... in as little as 15 years. The study, by ... zoology James Byers and published in the Aug. 11 ... response can evolve in an evolutionary nanosecond compared to ...

... genomic tools, it's a daunting task to find a ... being able to say not just when and how ... genetic change translated into real-world dominance of one population ... experiment that forced bacteria to compete in a head-to-head ...

... found in the venom of the brown recluse spider, researchers ... a new way to open molecular pores, called ion channels, ... MD, PhD; Yajamana Ramu, PhD; and Yanping Xu, MD, PhD ... over 100 poisonous invertebrate species to make this discovery. ...

Other Biology News:Mussels evolve quickly to defend against invasive crabs 2 Mussels evolve quickly to defend against invasive crabs 3 Ready, set, mutate?and may the best microbe win 2 Ready, set, mutate?and may the best microbe win 3 Gatekeeping: Penn researchers find new way to open ion channels in cell membranes 2

Mussels evolve quickly to defend against invasive crabs Ready, set, mutate?and may the best microbe win Gatekeeping: Penn researchers find new way to open ion channels in cell membranes

Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...

6-keto Prostaglandin F1α EIA Antiserum 6-keto-PGF1alpha EIAs prostaglandins antisera enzyme immunoassays reagents 6-keto-PGF1.alpha....

...

Ephrin A4...

Biology Products:

Rabbit Anti-GPCR G2A Polyclonal Antibody, Unconjugated from Abcam Anti-6-keto Prostaglandin F1 alpha (EIA Antiserum) Antibody, Unconjugated from Cayman Chemical BD FACSCanto flow cytometer from BD Biosciences - Immunocytometry Systems Rabbit Anti-Human Ephrin A4 Antibody, Unconjugated from Spring Bioscience

Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Prefe...( WALTHAM Mass. Sept. 15 /- Inverne...)